Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy

• Published in: Oncotarget Vol. 7; no. 15; pp. 19762 - 19780
• Main Authors: Tran, William T., Childs, Charmaine, Chin, Lee, Slodkowska, Elzbieta, Sannachi, Lakshmanan, Tadayyon, Hadi, Watkins, Elyse, Wong, Sharon Lemon, Curpen, Belinda, Kaffas, Ahmed El, Al-Mahrouki, Azza, Sadeghi-Naini, Ali, Czarnota, Gregory J.
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 12.04.2016
• Subjects: Adult; Aged; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Chemotherapy, Adjuvant; Female; Hemoglobins - analysis; Humans; Logistic Models; Middle Aged; Monitoring, Physiologic - methods; Multivariate Analysis; Optical Imaging - methods; Outcome Assessment, Health Care - methods; Reproducibility of Results; Research Paper; ROC Curve; Spectrum Analysis - methods; Ultrasonography - methods; quantitative ultrasound; neoadjuvant chemotherapy; locally advanced breast cancer; treatment monitoring; diffuse optical spectroscopy
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.7844

This study evaluated pathological response to neoadjuvant chemotherapy using quantitative ultrasound (QUS) and diffuse optical spectroscopy imaging (DOSI) biomarkers in locally advanced breast cancer (LABC). The institution's ethics review board approved this study. Subjects (n = 22) gave written informed consent prior to participating. US and DOSI data were acquired, relative to the start of neoadjuvant chemotherapy, at weeks 0, 1, 4, 8 and preoperatively. QUS parameters including the mid-band fit (MBF), 0-MHz intercept (SI), and the spectral slope (SS) were determined from tumor ultrasound data using spectral analysis. In the same patients, DOSI was used to measure parameters relating to tumor hemoglobin and composition. Discriminant analysis and receiver-operating characteristic (ROC) analysis was used to classify clinical and pathological response during treatment and to estimate the area under the curve (AUC). Additionally, multivariate analysis was carried out for pairwise QUS/DOSI parameter combinations using a logistic regression model. Individual QUS and DOSI parameters, including the (SI), oxy-hemoglobin (HbO2), and total hemoglobin (HbT) were significant markers for response after one week of treatment (p < 0.01). Multivariate (pairwise) combinations increased the sensitivity, specificity and AUC at this time; the SI + HbO2 showed a sensitivity/specificity of 100%, and an AUC of 1.0. QUS and DOSI demonstrated potential as coincident markers for treatment response and may potentially facilitate response-guided therapies. Multivariate QUS and DOSI parameters increased the sensitivity and specificity of classifying LABC patients as early as one week after treatment.